LensGen has closed on $10 million to help fund the Juvene IOL pivotal FDA study, according to a press release.
This initial funding is part of a larger Series B financing planned for 2021.
Juvene, a disruptive fluid-optic IOL, is under development for the treatment of cataract and presbyopia.
In addition, James V. Mazzo has been elected to the company’s board of directors.
“LensGen has a unique platform technology that I believe represents the future of cataract and lens replacement surgery,” Mazzo said in the release.
Uncategorized